Research progress of interleukin-15 in cancer immunotherapy

Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is essential for the development, proliferation, and activation of immune cells, including natural killer (NK) cells, T cells and B cells. Recent studies have revealed that interleukin-15 also plays a critical r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Menghan, Huang, Xuan, Huang, Xiting, Ju, Dianwen, Zhu, Yi Zhun, Ye, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213988/
https://www.ncbi.nlm.nih.gov/pubmed/37251333
http://dx.doi.org/10.3389/fphar.2023.1184703
_version_ 1785047745054113792
author Cai, Menghan
Huang, Xuan
Huang, Xiting
Ju, Dianwen
Zhu, Yi Zhun
Ye, Li
author_facet Cai, Menghan
Huang, Xuan
Huang, Xiting
Ju, Dianwen
Zhu, Yi Zhun
Ye, Li
author_sort Cai, Menghan
collection PubMed
description Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is essential for the development, proliferation, and activation of immune cells, including natural killer (NK) cells, T cells and B cells. Recent studies have revealed that interleukin-15 also plays a critical role in cancer immunotherapy. Interleukin-15 agonist molecules have shown that interleukin-15 agonists are effective in inhibiting tumor growth and preventing metastasis, and some are undergoing clinical trials. In this review, we will summarize the recent progress in interleukin-15 research over the past 5 years, highlighting its potential applications in cancer immunotherapy and the progress of interleukin-15 agonist development.
format Online
Article
Text
id pubmed-10213988
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102139882023-05-27 Research progress of interleukin-15 in cancer immunotherapy Cai, Menghan Huang, Xuan Huang, Xiting Ju, Dianwen Zhu, Yi Zhun Ye, Li Front Pharmacol Pharmacology Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is essential for the development, proliferation, and activation of immune cells, including natural killer (NK) cells, T cells and B cells. Recent studies have revealed that interleukin-15 also plays a critical role in cancer immunotherapy. Interleukin-15 agonist molecules have shown that interleukin-15 agonists are effective in inhibiting tumor growth and preventing metastasis, and some are undergoing clinical trials. In this review, we will summarize the recent progress in interleukin-15 research over the past 5 years, highlighting its potential applications in cancer immunotherapy and the progress of interleukin-15 agonist development. Frontiers Media S.A. 2023-05-12 /pmc/articles/PMC10213988/ /pubmed/37251333 http://dx.doi.org/10.3389/fphar.2023.1184703 Text en Copyright © 2023 Cai, Huang, Huang, Ju, Zhu and Ye. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cai, Menghan
Huang, Xuan
Huang, Xiting
Ju, Dianwen
Zhu, Yi Zhun
Ye, Li
Research progress of interleukin-15 in cancer immunotherapy
title Research progress of interleukin-15 in cancer immunotherapy
title_full Research progress of interleukin-15 in cancer immunotherapy
title_fullStr Research progress of interleukin-15 in cancer immunotherapy
title_full_unstemmed Research progress of interleukin-15 in cancer immunotherapy
title_short Research progress of interleukin-15 in cancer immunotherapy
title_sort research progress of interleukin-15 in cancer immunotherapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213988/
https://www.ncbi.nlm.nih.gov/pubmed/37251333
http://dx.doi.org/10.3389/fphar.2023.1184703
work_keys_str_mv AT caimenghan researchprogressofinterleukin15incancerimmunotherapy
AT huangxuan researchprogressofinterleukin15incancerimmunotherapy
AT huangxiting researchprogressofinterleukin15incancerimmunotherapy
AT judianwen researchprogressofinterleukin15incancerimmunotherapy
AT zhuyizhun researchprogressofinterleukin15incancerimmunotherapy
AT yeli researchprogressofinterleukin15incancerimmunotherapy

Ejemplares similares